Psilocybin Session Data Reporting And What clients Should Know

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

In regulated psilocybin services, you are usually asked to complete intake and consent forms, and some programs also require service providers to report aggregated or de-identified data to the state so the program can track access and safety trends.

Why programs collect session data

You will see data collection for two broad reasons. One is program oversight. A regulated system needs a way to confirm that required steps happened, records exist, products and doses are traceable, and adverse reactions are logged in a consistent way. In Oregon’s regulated services model, facilitators and service centers have defined recordkeeping duties tied to preparation, administration and integration, plus product identification and dose details, and adverse reaction records.

The second reason is evaluation at the program level. Some programs collect client demographic fields and high-level reasons for seeking services so they can track who is being served and where barriers show up. Oregon’s quarterly reporting rule lists demographic fields, reasons clients requested services, counts of sessions and denials, average psilocybin analyte dose per administration session, and aggregated counts of adverse reactions and post-session reactions.

You may also see statements that program-level data supports safety tracking and access evaluation. Oregon’s 303 Client Data Form describes the data as aggregated for statewide reporting and describes a goal of assessing safety and accessibility for different client populations, with an opt-out option for having responses included in the totals submitted.

Some states are building newer models that center de-identified outcome and public health tracking. Colorado’s 2025 implementation bill describes a state database focused on public health and program outcomes, with de-identified data and explicit limits on public release. It also describes new data reporting requirements for licensees beginning July 1, 2026.

What clients are commonly asked to provide

You can expect two different buckets of information. One bucket supports your session logistics and safety planning. The other bucket supports required reporting, where it exists.

For session logistics and safety planning, you will often be asked for basic identifying and contact information, an informed consent document, and details that help plan your arrival and departure. In Oregon, facilitators must create and share records with the service center that include an information form, an informed consent document, and a transportation plan. They also must record session dates and times and track product identification and how much product was consumed, plus any deviations from the transportation plan and any adverse behavioral or medical reactions.

Depending on the model, you may also see optional plans tied to extra support. Oregon’s recordkeeping rule lists support person plans and safety and support plans as records created when applicable.

For program reporting, you may be asked to complete a standardized client data form. In Oregon, the rule calls out aggregated client reporting fields like race, ethnicity, preferred spoken and written language, disability status, sexual orientation, gender identity, income, age, veteran status and county of residence where applicable, plus reasons clients requested services.

You should also expect basic session log information to exist on the provider side even when you are not asked to fill it out yourself. For example, Colorado’s regulations include requirements tied to reporting adverse health events within a set time window and maintaining administration session logs with fields like date, duration and number of participants.

Opt-out and consent steps

Opt-out and consent usually show up in three places. One is consent to participate in services at all. Another is consent to disclose identifiable information outside the required provider team. The third is opting out of certain types of reporting or disclosure in programs that allow it.

In Oregon’s model, you can opt out of having your 303 Client Data Form responses included in the aggregated totals submitted to the state program. The state page describing SB 303 data collection says clients have the option to check a box indicating they do not want their data submitted, and the 2026 form includes that opt-out language tied to the totals submitted.

That opt-out does not mean the form disappears. The program’s data privacy document states that service centers are required to store completed 303 Client Data Forms in each client file, and that the form is still stored even if you opted out of having your responses submitted in the compiled totals. It also states that no client records or copies may be stored at a location other than the service center where you participate or intend to participate in an administration session.

Separate from program reporting, you may see a consent requirement for disclosing identifiable client information. Oregon’s confidentiality rule describes limits on who can access client records and indicates a service center needs a completed client consent form to disclose identifiable client information, with required elements like what will be disclosed, who it goes to, the purpose, your signature and an expiration date.

You may also see disclosure and opt-out around de-identified data that a service center or facilitator could share with third parties for purposes like research or marketing. Oregon provides a required notice and an opt-out statement for disclosure of de-identified data by a service center or facilitator. The form defines de-identified data in practical terms and includes an optional opt-out statement for having your de-identified data disclosed to third parties by the named provider.

Other programs use a forms library approach for required disclosures. Colorado’s public forms page lists disclosure forms that include de-identified data and opt-out disclosures, plus privacy and confidentiality disclosures.

How data is stored and shared at a high level

You can think about storage and sharing in layers.

The first layer is your identifiable client record. In Oregon’s model, the rules and program guidance emphasize that records are stored at the service center and transferred there, with access limits for facilitators tied to clients they served. The informed consent rule reinforces that client records and copies must be stored at the service center where you participate or intend to participate.

The second layer is what the provider reports to the program. Oregon’s reporting rule requires service centers to aggregate and submit quarterly data, with a client opt-out for withholding client data from submission, and with rules stating that data may only be reported to the program and may not be shared except for representatives of the service center that collect and maintain the data.

The third layer is what becomes public. In Oregon’s description of SB 303 reporting and on the 303 form background text, the program describes compiling statewide data and de-identifying it before publishing to a data dashboard.

Confidentiality rules can sit above all layers. Oregon statute restricts disclosure of information that could identify a client or communications made during services, with exceptions that include client consent, certain safety-related disclosures and reporting required program data.

Some states are writing explicit limits into law for program databases. Colorado’s 2025 bill describes a de-identified database as confidential and not subject to open records, subpoena, discovery, or civil court use, with limited release for approved research, public health tracking and regulatory duties and with a requirement to release only the minimum necessary data without personal identifying information.

Privacy questions to ask before you participate

You can get clearer quickly if you ask direct questions that map to the layers above. You are trying to understand what is required for service delivery, what is required for program reporting and what is optional disclosure.

Here are questions that fit most regulated models.

  • Ask where your identifiable records are stored and who can access them day to day. Oregon’s rules place storage at the service center and limit facilitator access to clients they served unless you give written consent.
  • Ask which forms you must complete before services start. In Oregon, recordkeeping includes an information form, an informed consent document and a transportation plan, and providers must record product identification, dose details and adverse reactions.
  • Ask what gets reported to the state program and in what form. Oregon requires aggregated quarterly reporting that includes demographic fields, reasons for requesting services, counts of sessions and denials, an average psilocybin analyte dose and aggregated adverse reaction counts.
  • Ask if you can opt out of having your responses included in aggregated reporting totals. Oregon’s client data form includes an opt-out checkbox, and program guidance describes that option.
  • Ask what happens to the form if you opt out. Oregon’s program privacy document says the completed form is still stored in your client file even when you opt out of having responses submitted in the compiled totals.
  • Ask if the provider shares de-identified data with third parties for any purpose and what opt-out exists. Oregon provides a required notice and opt-out statement for disclosure of de-identified data by a service center or facilitator.
  • Ask how long records are kept and how corrections work if you spot an error. You may see retention and correction practices described in program guidance or provider policy, and you can ask for the version you will sign.
  • Ask how adverse reactions are documented and reported. Oregon requires recording adverse reactions at the provider record level and reporting aggregated counts quarterly, and Colorado’s rules include a short timeline for reporting adverse health events to the state division.

What good reporting can improve over time

When reporting is consistent and privacy controls are clear, programs can learn without putting client identities at risk. You usually see three areas of improvement.

One area is safety tracking that stays grounded in program operations. Oregon’s reporting rule calls for aggregated counts of adverse reactions and post-session reactions, and it also calls for reporting in a way that protects confidentiality and prevents unauthorized access.

Another area is access and equity monitoring. Oregon’s 303 client form background text frames demographic reporting as a way to describe who is receiving services and to support evaluation of accessibility for different client populations. That helps programs and the public see trends in who is served and who is not.

A third area is clearer baselines for what programs can responsibly publish. Oregon describes compiling statewide data and de-identifying it before publishing on a dashboard. That gives you a way to watch trends without tying data back to individual people.

You can also expect 2026 to bring more formal outcome tracking in some places. Colorado’s 2025 law describes a de-identified public health database and sets July 1, 2026 as the start date for de-identified data reporting requirements for licensees.

If you are comparing regulated service program reporting to research studies, keep in mind that program reporting is built for oversight and public health tracking. Clinical trials use separate protocols, data governance and consent language. If you want a quick reference point while you are already thinking about that difference, you can scan this internal page on clinical trial context. clinical trial context

We are Rose Hill Life Sciences, a psychedelic research organization specializing in the production and research of Psilocybe cubensis, operating at the intersection of science and therapeutic integration. We are based in Massachusetts.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.